Breed s Hill Capital LLC Has $1.26 Million Position in Abbott Laboratories (NYSE:ABT)

Breed s Hill Capital LLC boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 37.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,120 shares of the healthcare product maker's stock after buying an additional 3,033 shares during the quarter. Abbott Laboratories makes up approximately 0.7% of Breed s Hill Capital LLC's portfolio, making the stock its 26th biggest position. Breed s Hill Capital LLC's holdings in Abbott Laboratories were worth $1,258,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Redwood Park Advisors LLC acquired a new position in Abbott Laboratories during the 4th quarter worth about $25,000. Noble Wealth Management PBC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. NewSquare Capital LLC lifted its stake in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after purchasing an additional 105 shares during the period. WealthTrak Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $28,000. Finally, Rialto Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $29,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 1.2%

Abbott Laboratories stock opened at $131.46 on Friday. The stock has a market cap of $228.72 billion, a P/E ratio of 17.18, a PEG ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23. The firm's fifty day moving average price is $129.77 and its 200-day moving average price is $124.52. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. UBS Group boosted their price objective on Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Raymond James upped their target price on Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, April 17th. Stifel Nicolaus upped their target price on Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Jefferies Financial Group upped their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research note on Thursday, April 17th. Finally, Argus upgraded Abbott Laboratories to a "strong-buy" rating in a research note on Tuesday, January 28th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $142.59.

Insider Transactions at Abbott Laboratories

In related news, SVP Eric Shroff sold 562 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the transaction, the senior vice president now owns 31,970 shares of the company's stock, valued at $4,417,294.90. This represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sally E. Blount sold 2,600 shares of the stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,278 shares of company stock valued at $12,745,859. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.